Literature DB >> 26503649

Bioassay for Determining Voriconazole Serum Levels in Patients Receiving Combination Therapy with Echinocandins.

Maria Siopi1, Efthymios Neroutsos2, Kalliopi Zisaki3, Maria Gamaletsou4, Maria Pirounaki5, Panagiotis Tsirigotis6, Nikolaos Sipsas4, Aristides Dokoumetzidis2, Evgenios Goussetis3, Loukia Zerva1, Georgia Valsami2, Joseph Meletiadis7.   

Abstract

Voriconazole levels were determined with high-performance liquid chromatography (HPLC) and a microbiological agar diffusion assay using a Candida parapsilosis isolate in 103 serum samples from an HPLC-tested external quality control program (n = 39), 21 patients receiving voriconazole monotherapy (n = 39), and 7 patients receiving combination therapy (n = 25). The results of the bioassay were correlated with the results obtained from the external quality control program samples and with the HPLC results in sera from patients on voriconazole monotherapy and on combination therapy with an echinocandin (Spearman's rank correlation coefficient [rs], > 0.93; mean ± standard error of the mean [SEM] % difference, <12% ± 3.8%).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26503649      PMCID： PMC4704192          DOI： 10.1128/AAC.01688-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry.

Authors:  Brian G Keevil; Sheila Newman; Stephen Lockhart; Susan J Howard; Caroline B Moore; David W Denning
Journal:  Ther Drug Monit       Date:  2004-12       Impact factor: 3.681

2.  Comparison of microbiological and UV-spectrophotometric assays for determination of voriconazole in tablets.

Authors:  Andréa I H Adams; Martin Steppe; Pedro E Fröehlich; Ana M Bergold
Journal:  J AOAC Int       Date:  2006 Jul-Aug       Impact factor: 1.913

3.  Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.

Authors:  Kathrin Heyn; Antje Tredup; Stefanie Salvenmoser; Frank-Michael C Müller
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

5.  Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B.

Authors:  R L Kaspar; D J Drutz
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

6.  Comparison of high-performance liquid chromatography and bioassay of amphotericin B in serum.

Authors:  J W Hülsewede; H Dermoumi
Journal:  Mycoses       Date:  1994 Jan-Feb       Impact factor: 4.377

7.  Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.

Authors:  Steve Trifilio; Gennethel Pennick; Judy Pi; Jennifer Zook; Mary Golf; Kimberley Kaniecki; Seema Singhal; Stephanie Williams; Jane Winter; Martin Tallman; Leo Gordon; Olga Frankfurt; Andrew Evens; Jayesh Mehta
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

8.  Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods.

Authors:  Andres Pascual; Valérie Nieth; Thierry Calandra; Jacques Bille; Saskia Bolay; Laurent A Decosterd; Thierry Buclin; Paul A Majcherczyk; Dominique Sanglard; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

9.  Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.

Authors:  L Purkins; N Wood; P Ghahramani; K Greenhalgh; M J Allen; D Kleinermans
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079
View more
  6 in total

1.  Agar Bioassays for Antifungals in Combination Therapy.

Authors:  Marife Martinez; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

2.  Reply to "Agar Bioassays for Antifungals in Combination Therapy".

Authors:  Maria Siopi; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 3.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

4.  Toward Harmonization of Voriconazole CLSI and EUCAST Breakpoints for Candida albicans Using a Validated In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Maria-Ioanna Beredaki; Panagiota-Christina Georgiou; Maria Siopi; Lamprini Kanioura; David Andes; Maiken Cavling Arendrup; Johan W Mouton; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  A Prospective Multicenter Cohort Surveillance Study of Invasive Aspergillosis in Patients with Hematologic Malignancies in Greece: Impact of the Revised EORTC/MSGERC 2020 Criteria.

Authors:  Maria Siopi; Stamatis Karakatsanis; Christoforos Roumpakis; Konstantinos Korantanis; Helen Sambatakou; Nikolaos V Sipsas; Panagiotis Tsirigotis; Maria Pagoni; Joseph Meletiadis
Journal:  J Fungi (Basel)       Date:  2021-01-05

Review 6.  Invasive Fungal Infections in Patients with Hematological Malignancies: Emergence of Resistant Pathogens and New Antifungal Therapies.

Authors:  Maria N Gamaletsou; Thomas J Walsh; Nikolaos V Sipsas
Journal:  Turk J Haematol       Date:  2018-02-02       Impact factor: 1.831
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.